Cardiovascular Risk
Read Time: 5 mins

APOC3 Interference for Familial Chylomicronaemia Syndrome

Copy Link
Published Online: Nov 1st 2022 touchREVIEWS in Endocrinology. 2022;18(2):82-3 DOI:
Authors: Robert A Hegele
Quick Links:
Article Information

Patients with familial chylomicronaemia syndrome (FCS) have severe hypertriglyceridaemia due to genetically absent lipolytic capacity. They have a poor response to conventional therapies. To reduce the risk of potentially fatal pancreatitis, the management of FCS relies principally on a strict low-fat diet, which is difficult to follow and compromises quality of life. Targeted reduction of apolipoprotein C-III using new anti-APOC3 agents, such as the short interfering RNA ARO-APOC3, represents a promising approach to correct the severe biochemical disturbance in FCS.


Apolipoprotein C-II, apolipoprotein C-III, chylomicrons, hyperlipoproteinemia type 1, hyperlipoproteinemia type 5, lipoprotein lipase, lipoproteins, pancreatitis, recessive disorder, triglycerides


Chylomicronaemia refers to the pathological presence of large, circulating, intestinally derived chylomicrons.1 Clinical features of chylomicronaemia syndrome include lipaemic plasma, lipaemia retinalis, eruptive xanthomas, hepatosplenomegaly, neurological symptoms such as mental fog and mood changes and, most importantly, increased risk of acute pancreatitis.1,2 When smaller atherogenic triglyceride (TG)-rich lipoproteins are concomitantly elevated, the risk of myocardial infarction and stroke is also increased.2 Fasting plasma TG concentration of >10 mmol/L (>880 mg/dL), which occurs in approximately 1 in 400 North American adults,3 is associated with chylomicronaemia. Chylomicrons accumulate when endothelial-bound lipoprotein lipase (LPL) becomes saturated by excessive levels of TG-rich lipoproteins.1,2 Secondary factors that exacerbate chylomicronaemia include alcohol use, diets high in fat and simple carbohydrates, uncontrolled diabetes, obesity, insulin resistance, non-alcoholic fatty liver disease, pregnancy and medications including corticosteroids, oral oestrogens, psychotropic drugs, and immunosuppressants.1,2 This condition is called multifactorial chylomicronaemia syndrome (MCS), and it is the most common form of chylomicronaemia.2

In contrast, a tiny subset of patients with severe hypertriglyceridaemia has familial chylomicronaemia syndrome (FCS) caused by an inherited complete loss of LPL activity.1 FCS is found in 1 in 100,000–1,000,000 individuals.4,5 FCS results from biallelic pathogenic variants in the LPL gene encoding LPL or in the glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 (GPIHBP1), apolipoprotein A5 (APOA5), apolipoprotein C2 (APOC2) and lipase maturation factor 1 (LMF1) genes encoding GPIHBP1, apolipoprotein (apo) A-V, apo C-II and LMF1, respectively.1 Because FCS is a single-gene disorder, symptoms, including failure to thrive, can begin in infancy or childhood.1 FCS is stressful for patients, families and care providers since current treatment options are very limited, except for a draconian fat-restricted diet that provides around 15% of calories as fat to reduce the substrate enterocytes use to synthesize chylomicrons.2,4 Traditional TG-reducing treatments, such as fibrates, niacin and omega-3 fatty acids, are minimally effective.4

In pre-genomic times, FCS was diagnosed biochemically by demonstrating the absence of lipolytic activity in plasma after heparin infusion, although the assay was cumbersome and somewhat variable.1,2 Currently, genetic diagnosis is the gold standard for FCS.1,5 Reducing TGs to <5.6 mmol/L (<500 mg/dL) in FCS is associated with reduced pancreatitis risk.1,4 In adults with FCS, dietary adherence is challenging, and relapsing pancreatitis often occurs.4 Plasmapheresis has been suggested in some cases, but its effects are very transient; furthermore, it is invasive, incurs costs, requires specialized equipment, is not without risk and does not improve survival.4 Other proposed treatments, such as inhibitors of microsomal TG transfer protein, apo B, diacylglycerol acyl transferase 1 and angiopoietin-like protein 3, all have limitations.4 There is a critical unmet need for new treatments for FCS.4

Apo C-III, a 79 amino acid protein that circulates with chylomicrons and other lipoproteins, is a promising treatment target in chylomicronaemia.6 The effects of apo C-III on lipoprotein metabolism include promoting the secretion of TG-rich lipoproteins, interfering with LPL activity and interfering with the receptor-dependent and -independent clearance of TG-rich lipoproteins.6 Furthermore, classical biochemical, transgenic animal, family and Mendelian randomization studies in aggregate indicate that silencing hepatic APOC3, for example, with antisense oligonucleotides (ASOs) or RNA interference approaches, will reduce TG levels.6

The value of knocking down apo C-III in FCS was first shown in the APPROACH (A study of volanesorsen [formerly IONIS-APOCIIIRx] in patients with familial chylomicronemia syndrome; identifier: NCT02211209) study, a phase III, multi-institutional, randomized, double-blind, placebo-controlled trial of volanesorsen, an ASO that binds APOC3 mRNA in the nucleus and inhibits its translation.7,8 In APPROACH, 66 patients were studied, 52 of whom had genetically diagnosed FCS: 33 received volanesorsen 300 mg subcutaneously once weekly, and 33 received matching doses of placebo.7,9 At 3 months, volanesorsen was associated with placebo-adjusted reductions of around 90% in apo C-III and TG levels, with beneficial effects found across multiple lipoprotein subfractions. However, thrombocytopenia (platelets <100,000/μL) occurred in 15 of 33 participants receiving volanesorsen compared with none who received the placebo. Two participants in the volanesorsen group had platelets <25,000/μL.7 Thrombocytopenia was considered to result from a chemical property of volanesorsen itself rather than from the mechanism for targeting apo C-III. The risk of thrombocytopenia necessitated routine platelet monitoring and mandated dose down-titration and/or corticosteroid administration.7 Volanesorsen for FCS was eventually approved with restrictions in Europe but not in North America.10,11

Two novel agents targeting APOC3 are in clinical development in the hope of retaining the benefits of volanesorsen while avoiding thrombocytopenia. The first, olezarsen (formerly AKCEA-APOCIII-LRx) is an N-acetylgalactosamine (GalNAc)-conjugated ASO that enters the hepatocytes via the asialoglycoprotein receptor, which allows for reduced dosing that maintains efficacy with better safety than volanesorsen.6,12 In patients with moderate hypertriglyceridaemia who received subcutaneous injections of olezarsen, mean TG levels were reduced by up to 67% compared with placebo.12 Occasional mild injection-site reactions but no thrombocytopenia were noted.12 An on-going phase III, multi-centre, randomized, double-blind, placebo-controlled study called BALANCE (A study of olezarsen [formerly known as AKCEA-APOCIII-LRx] administered to patients with familial chylomicronemia syndrome; identifier: NCT04568434) is evaluating the efficacy of olezarsen administered monthly over a year via subcutaneous injection in adults with FCS.13

A second novel apo C-III antagonist, ARO-APOC3, is a GalNAc-bound RNA interference that targets APOC3 mRNA within the cytoplasm of hepatocytes, resulting in prolonged suppression of apo C-III.6,14 A phase I trial in patients with severe hypertriglyceridaemia, including some with FCS, showed that ARO-APOC3 was associated with reductions of up to 96% and 92% in apo C-III and TG levels, respectively.14 An on-going phase III, randomized, double-blind, placebo-controlled trial called PALISADE (AROAPOC3-3001; Study of ARO-APOC3 in adults with familial chylomicronemia syndrome; identifier: NCT05089084) commenced in January 2022 to evaluate the efficacy and safety of ARO-APOC3 in patients with FCS.15 A planned 60 adults with TG ≥10 mmol/L (≥880 mg/dL) and genetically diagnosed FCS are being randomized to receive either ARO-APOC3 25 mg or 50 mg subcutaneously every 3 months (n=20 for each dose) or volume-matched saline placebo (N=10 for each treatment group).15,16 The primary endpoint is the change from the baseline of fasting TG at 10 months, with several secondary and exploratory endpoints.15 After 12 months, the participants will be invited to continue in an open-label extension study.16

Both the PALISADE and BALANCE studies offer new hope for patients with FCS, who are among the most challenging in lipidology to manage. Achieving sustained TG reduction alongside other potential metabolic and clinical benefits and minimal adverse effects would be a major advance. Furthermore, a favourable benefit-to-risk ratio of new treatments in FCS could have implications for patients with MCS, which is at least 50- to 100-times more common than FCS.6 While the relative risk of pancreatitis is lower in patients with MCS than in those with FCS, the absolute number of acute pancreatitis episodes across all MCS patients is substantial.17 A clinically relevant subgroup (perhaps 5–10%) of patients with MCS with refractory or sustained chylomicronaemia might particularly benefit from ARO-APOC3 or olezarsen. Such patients are operationally equivalent to those with genetic FCS. New nomenclatures such as ‘refractory’ or ‘sustained’ chylomicronaemia might be appropriate for patients with true genetic FCS; extreme cases of MCS due to heterozygous pathogenic variants or high polygenic risk of hypertriglyceridaemia18; other unusual combinations of rare genetic variants; low LPL biochemical activity with high clinical suspicion for FCS based on clinical scoring19 but negative for genetic findings; persistent autoantibodies against GPIHBP1 or LPL20; or potential new non-Mendelian disease mechanisms, such as methylation. While most patients with chylomicronaemia do not have true genetic FCS, some might still similarly benefit from effective and well-tolerated anti-APOC3 therapies. Future clinical trials comparing anti-APOC3 therapies with other newer agents will decide their role not only in patients with FCS but also in the more common MCS and other forms of hypertriglyceridaemia.

Article Information:

Robert A Hegele reports consulting fees from Acasti, Aegerion, Akcea/Ionis, Amgen, Arrowhead, HLS Therapeutics, Novartis, Pfizer, Regeneron and Sanofi. Robert A Hegele is supported by the Jacob J Wolfe Distinguished Medical Research Chair, the Edith Schulich Vinet Research Chair and the Martha G Blackburn Chair in Cardiovascular Research. Robert A Hegele holds operating grants from the Canadian Institutes of Health Research (Foundation award), the Heart and Stroke Foundation of Ontario (G-21-0031455) and the Academic Medical Association of Southwestern Ontario (INN21-011).

Compliance With Ethics

This article is an opinion piece and does not report on new clinical data or any studies with human or animal subjects performed the author.

Review Process

Double-blind peer review.


The named author meets the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, takes responsibility for the integrity of the work as a whole, and has given final approval for the version to be published.


Robert A Hegele, Departments of Medicine (Division of Endocrinology) and Biochemistry, Western University, 1151 Richmond St, London, ON N6A 3K7, Canada. E:


No funding was received in the publication of this article.


This article is freely accessible at © Touch Medical Media 2022

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analysed during the writing of this article.




  1. Brahm AJ, Hegele RA. Chylomicronaemia–current diagnosis and future therapies. Nat Rev Endocrinol. 2015;11:352–62.
  2. Chait A, Eckel RH. The chylomicronemia syndrome Is most often multifactorial: A narrative review of causes and treatment. Ann Intern Med. 2019;170:626–34.
  3. Berberich AJ, Ouédraogo AM, Shariff SZ, et al. Incidence, predictors and patterns of care of patients with very severe hypertriglyceridemia in Ontario, Canada: A population-based cohort study. Lipids Health Dis.2021;20:98
  4. Shamsudeen I, Hegele RA. Safety and efficacy of therapies for chylomicronemia. Expert Rev Clin Pharmacol. 2022;15:395–405.
  5. Dron JS, Hegele RA. Genetics of hypertriglyceridemia. Front Endocrinol.2020;11:455.
  6. Hegele RA. Apolipoprotein C-III inhibition to lower triglycerides: One ring to rule them all?Eur Heart J. 2022;43:1413–5.
  7. Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome.N Engl J Med. 2019; 381:531–42.
  8. gov. The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome. Identifier: NCT02211209. Available at: 20 September 2022).
  9. Hegele RA, Berberich AJ, Ban MR, et al. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.J Clin Lipidol. 2018;12:920–7.
  10. European Medicines Agency. Waylivra. Available at:  (accessed 20 September 2022).
  11. S. Food and Drug Administration. FDA Briefing Document: Endocrinologic and Metabolic Drugs Advisory Committee Meeting, 10 May 2019. Available at: (accessed 20 September 2022).
  12. Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43:1401–12.
  13. gov. A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) (BALANCE). Identifier: NCT04568434. Available at: 20 September 2022).
  14. Clifton P, Sullivan D, Baker J, et al. Pharmacodynamic effect of ARO-APOC3, an investigational hepatocyte-targeted RNA interference therapeutic targeting apolipoprotein C3, in patients with hypertriglyceridemia and multifactorial chylomicronemia. Circulation. 2020;14:Abstract 12594.
  15. gov. Study of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome (FCS) (PALISADE). Identifier: NCT05089084. Available at: 20 September 2022).
  16. Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals initiates phase 3 PALISADE study of ARO-APOC3 for treatment of familial chylomicronemia syndrome. Available at: 20 September 2022).
  17. Paquette M, Bernard S, Hegele RA, Baass A. Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia. Atherosclerosis. 2019;283:137–42.
  18. Dron JS, Wang J, Cao H, et al. Severe hypertriglyceridemia is primarily polygenic.J Clin Lipidol. 2019;13:80–8.
  19. Stroes E, Moulin P, Parhofer KG, et al. Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl. 2017;23:1–7.
  20. Miyashita K, Lutz J, Hudgins LC, et al. Chylomicronemia from GPIHBP1 autoantibodies.J Lipid Res. 2020;61:1365–76.

Further Resources

Share this Article
Related Content In Cardiovascular Risk
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72